Value-Based Cancer Care Issues


June 2011, Vol 2, No 3

New Formulation of Levoleucovorin Approved

FDA Approvals, News & Updates

A new, ready-to-use (RTU) injectable formulation of the folate analog levoleucovorin (Fusilev; Spectrum Pharmaceuticals) received FDA approval. Like the previously approved lyophilized formulation, the RTU formulation is indicated for rescue after high-dose methotrexate therapy in the treatment of osteosarcoma. Levoleucovorin [ Read More ]

Abiraterone Improves Overall Survival in Metastatic Prostate Cancer

Uncategorized

Androgen deprivation has long been the standard of care for men with advanced prostate cancer, preventing or delaying the recurrence of metastases. Recent results have demonstrated that the androgen biosynthesis inhibitor abiraterone acetate prolongs overall survival in patients with metastatic [ Read More ]

Patients, Pathways,the Focus of ASCO Presidents

Uncategorized

Chicago, IL—Addressing the many attendees at the American Society of Clinical Oncology (ASCO) annual meeting, outgoing President George Sledge Jr, MD, of Indiana University Simon Cancer Center, said, “I think I could write the history of our specialty by looking [ Read More ]

Assay Aids Patient Selection for Temozolomide in Glioblastoma

Uncategorized

Chicago, IL—Aprognostic marker that can be identified with a commercial test can identify patients with newly diagnosed glioblastoma who would benefit from life-prolonging temozolomide treatment, according to Mark R. Gilbert, MD, Professor, Department of Neuro-oncology, at the Division of Cancer [ Read More ]

Personalized Medicine Comes of Age at ASCO 2011

Uncategorized

Chicago, IL—Personalized medicine was the subject of the first press conference held at ASCO 2011 and the topic of one of the scientific sessions. Large-Scale Evidence for Benefits of Targeted Therapies Apostolia M. Tsimberidou, MD, PhD, Associate Professor, Department of [ Read More ]

Metabolic Syndrome a High Risk for Liver Cancer

Uncategorized

Orlando, FL—New results presented at the meeting suggest that the metabolic syndrome, which is strongly associated with diabetes and heart disease (and is characterized by elevated fasting glucose levels, central adiposity, dyslipoproteinemia, and hypertension), appears to also be strongly linked [ Read More ]

Chemo-Immunotherapy Regimen Boosts Survival in CRC

Uncategorized

Orlando, FL—A regimen that combines immunotherapy with chemotherapy doubled the overall survival (OS) time in patients with advanced colorectal cancer (CRC) over a standard chemotherapy regimen alone and improved progression-free survival (PFS), reported Pierpaolo Correale, MD, PhD, of Siena University [ Read More ]

Chemo-Immunotherapy Regimen Boosts Survival in CRC

Uncategorized

Orlando, FL—A regimen that combines immunotherapy with chemotherapy doubled the overall survival (OS) time in patients with advanced colorectal cancer (CRC) over a standard chemotherapy regimen alone and improved progression-free survival (PFS), reported Pierpaolo Correale, MD, PhD, of Siena University [ Read More ]

Cancer Drug Use and Costs Sharply Rising

Health Policy

There is no end in sight to the rising cost of fighting cancer, according to Medco’s 2011 Drug Trend Report (www.drugtrendreport.com/2011-report), which forecasted the cost of cancer drugs will grow 34% to 42% over the next 3 years. Medco predicts [ Read More ]

Recommendations for Optimal Myeloid Growth Factors Use

Uncategorized

Hollywood, FL—The evidence for the use of myeloid growth factors in patients at high risk for febrile neutropenia (FN) is solid, Jeffrey Crawford, MD, of Duke Cancer Institute, Durham, NC, told attendees at the 2011 National Comprehensive Cancer Network (NCCN) [ Read More ]

Hepatitis B a Risk with Chemotherapy

Uncategorized

Hollywood, FL—Patients receiving chemotherapy are at risk for reactivation of the hepatitis B virus (HBV), which can result in negative outcomes, including death from liver failure. According to Emmy Ludwig, MD, of Memorial Sloan-Kettering Cancer Center (MSKCC), New York, one [ Read More ]

Oncology 2021: Cost, FDA, and Cancer Care

Uncategorized

Washington, DC—Oncology and health care are undergoing rapid changes. One thing that does not seem to be changing soon is the long-term prognosis of exploding costs. The extent to which the US Food and Drug Administration (FDA) and the Centers [ Read More ]

Integrating a Wellness Perspective into Survivorship Care

Uncategorized

Washington, DC—Improved treatment, more effective screening, and an aging population have fueled the rapid growth of cancer survivors—approximately 12 million today in the United States, up from just 3 million in 1971. Since even before the Institute of Medicine’s pivotal [ Read More ]

Optimal Screening Method for Colorectal Cancer Still Debated

Uncategorized

San Francisco, CA—Colorectal cancer is preventable but remains the secondleading cause of cancer death, because of persistently low screening rates. At the 2011 Gastrointestinal Cancers Symposium, colorectal cancer screening experts debated the relative merits of 2 modalities competing for patients [ Read More ]

A Pharmacist Reviews Cancer Drugs in the Pipeline

Uncategorized

Few prolong survival but most offer reduced toxicity Salt Lake City, UT—A review of promising investigational drugs at the 2011 Hematology/Oncology PharmacyAssociation annual meeting shows that the pharmaceutical industry is responding to the call for more targeted agents in oncology. [ Read More ]